Unlock instant, AI-driven research and patent intelligence for your innovation.

Mutant Bordetella strains and methods of use thereof

By developing the Bordetella pertussis adhesin-deficient strain BPZE1P, we have solved the challenges of attenuation and immunogenicity of existing vaccines and achieved effective immune responses and protection against respiratory inflammation without causing pathology. The protection significantly reduces the development of airway inflammation.

Pending Publication Date: 2022-07-22
INST PASTEUR +1
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Of these, despite modern molecular biology techniques and major advances in our understanding of microbiology and immunology, it remains difficult to produce sufficiently attenuated without causing significant pathology, while being sufficiently immunogenic to induce Vaccine products for potent and long-lasting immune responses to target pathogens
Achieving an optimal level of attenuation is particularly troublesome in the case of attenuated whole-cell live bacterial vaccines, as over-attenuation by reducing the amount or activity of virulence factors can lead to poor immunogenicity and / or poor immunogenicity after administration. Vaccines that do not survive or replicate in the body long enough to induce an immune response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0064] Example 1 - Construction and characterization of a pertussis adhesin-deficient strain of Bordetella pertussis.

[0065] Escherichia coli DH5α, SM10 and Bordetella pertussis BPZE1, BPSM (Menozzi et al., Infect Immun [Infection and Immunity] 1994;62:769-778) and B1917 (Bart et al. Genome Announc [Genome Bulletin] 2014;2(6)). Bordetella strains were grown on Bordet-Gengou agar (BG) supplemented with 1% glycerol and 10% defibrinated sheep blood at 37°C. After growth, bacteria were harvested by scraping the plate and resuspended in phosphate buffered saline (PBS) at the desired density. For liquid cultures, Bordetella strains were grown at 37°C in a modified Stainer- Grow in Scholte medium (Imaizumi et al. Infect Immun [Infection and Immunity] 1983;41:1138-1143). The E. coli strains used for the cloning procedure were grown in LB broth or LB agar plates. Streptomycin (Sm) at 100 μg / ml, gentamicin (Gm) at 10 μg / ml, and ampicillin (Amp) at 100 μg / ml were used as needed.

...

example 2

[0068] Example 2 - BPZE1P colonizes mice like BPZE1.

[0069] As previously described (Mielcarek et al., supra), with 10 6 Groups of 18 6-week-old mice were inoculated intranasally with 20 μl of PBS with live bacteria. At the indicated time points (3 hours, 3 days, 7 days, 14 days, 21 days, and 28 days), 3 mice per group were sacrificed, and lungs were harvested and homogenized to measure the total number of colony forming units (CFUs). . Statistical analysis was performed by two-way ANOVA test using post hoc comparative Bonferroni test (95% confidence interval). see figure 2 , BPZE1 and BPZE1P colonize the animals equally well. Both strains exhibited a proliferation peak 3 days after vaccination, and colonization continued for 4 weeks. No statistically significant differences were observed between these strains in their ability to colonize mouse lungs.

example 3

[0070] Example 3 - BPZE1P is as immunogenic as BPZE1 and protective against virulent Bordetella pertussis challenge.

[0071] BPZE1P-induced immunity compared to BPZE1 was measured by antibody titration of mouse immune sera after nasal vaccination. with 10 5 Groups of 8 mice were intranasally inoculated with live BPZE1 or BPZE1P. After 4 weeks, mice were bled and total IgG titers were measured against total BPSM lysates. Blood was centrifuged at 5,000 x g for 5 minutes to separate serum from cells. Antibody titers against B. pertussis were estimated using an enzyme-linked immunosorbent assay (ELISA) as previously described (Mielcarek et al., supra), lysed using total B. pertussis BPSM at 1 μg total protein per well thing. Statistical analysis was performed using GraphPad Prism software. like image 3 As shown, BPZE1 and BPZE1P vaccinated mice exhibited much higher antibody titers than naive control mice. No significant differences in antibody titers were detected betwee...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present application relates to mutant Bordetella strains and methods of use thereof. A method of reducing or preventing the development of airway inflammation in a subject comprises the step of infecting the respiratory tract of the subject with an amount of a composition comprising a pharmaceutically acceptable carrier and an attenuated Bordetella pertussis adhesin-deficient Bordetella viable bacterium sufficient to colonize in the respiratory tract of the subject. The step of infecting a subject with an attenuated Bordetella pertussis adhesin-deficient Bordetella live bacterium results in a reduction or prevention of airway inflammation development in the subject.

Description

[0001] This application is a divisional application of the application dated March 29, 2017, the application number is 201780021384.7, and the invention name is "mutant Bordetella strains and methods of use thereof". [0002] CROSS-REFERENCE TO RELATED APPLICATIONS [0003] This application claims priority to US Provisional Patent Application Serial No. 62 / 314,843, filed March 29, 2016. [0004] sequence listing [0005] This application contains a Sequence Listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy created on March 27, 2017 is named 7056-0073_SL.txt and is 2,134 bytes in size. technical field [0006] The present invention generally relates to the fields of microbiology, immunology, allergy and medicine. More specifically, the present invention relates to live attenuated strains of Bordetella pertussis deficient in pertactin and their use as prophylactic and therapeutic agents in v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61P11/00A61P29/00
CPCA61K35/74A61P11/00A61P29/00A61P11/06A61P31/04A61K39/099C07K14/235C12N1/36A61K2039/51A61K2039/543A61K2039/575A61K35/00A61K2039/10A61K2039/58A61K35/42A61K9/007A61K2039/522
Owner INST PASTEUR